title: Vedolizumab for the treatment of ulcerative colitis.
abstract: BACKGROUND
  With a need for a larger armamentarium of therapeutic options for those suffering from moderate-to-severe ulcerative colitis, vedolizumab, an α4β7-integrin biologic therapy, has recently received approval in the United States, Canada and Europe. However, it is unclear where it should be positioned in relation to current therapies for moderate-to-severe ulcerative colitis.
  
  
  METHODS
  We systematically reviewed the literature for phase 1, phase 2 and phase 3 randomized controlled trials assessing the role of vedolizumab in ulcerative colitis.
  
  
  CONCLUSIONS
  Trials assessing vedolizumab highlight its arrival as an effective and safe therapy for patients suffering from ulcerative colitis.
authors.affiliation: a Division of Gastroenterology, Department of Medicine , University of British Columbia , Vancouver , BC , Canada.
authors.forename: Neal
authors.initials: N
authors.lastname: Shahidi
authors.affiliation: a Division of Gastroenterology, Department of Medicine , University of British Columbia , Vancouver , BC , Canada.
authors.forename: Brian
authors.initials: B
authors.lastname: Bressler
authors.affiliation: b Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology , University of Calgary , Rm 6D32, TRW Building, 3280 Hospital Drive Northwest, Calgary , AB , Canada T2N 4N1.
authors.forename: Remo
authors.initials: R
authors.lastname: Panaccione
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D016023:Integrins / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D016023:Integrins; C071777:integrin alpha4beta7; C543529:vedolizumab
keywords: IBD; UC; inflammatory bowel disease; integrins